Latest uniQure News & Updates

See the latest news and media coverage for uniQure. We track all announcements, press releases, and industry mentions in real time, all in one place.

uniQure

Gene therapy company targeting neurological and rare diseases

uniqure.com

Headquarters: Amsterdam, Netherlands
Founded year: 1998
Company type: Public company
Number of employees: 50–350
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about uniQure

In short: uniQure submitted regulatory applications for its Huntington's gene therapy AMT-130 following a favorable policy shift by the FDA.

Company announcements

September 7 uniQure

uniQure presents Fabry gene therapy safety updates at SSIEM 2026

Representatives shared clinical findings at the European conference in Helsinki, fostering discussions with researchers about future therapeutic strategies for the metabolic disorder.

September 4 uniQure

uniQure hosts inaugural Visiting Professors Lecture on Huntington’s disease

The Lexington office welcomed two University of Buffalo experts who shared clinical insights for improving patient management during the event.

September 2 uniQure

uniQure submits regulatory applications for investigational gene therapy AMT-130

The company filed a Biologics License Application with the U.S. FDA and a Marketing Authorisation Application with the United Kingdom’s MHRA for potential treatment of Huntington’s disease.

August 27 uniQure

uniQure presents AMT-130 data at a Latin American medical conference

Executive Director Steven Casto will share findings on the gene therapy candidate during the September event in Medellin, Colombia.

Media coverage

September 9 STAT

What to expect from UniQure's upcoming Huntington's gene therapy readout

Before the end of September, UniQure is expected to report four-year results from the closely tracked clinical trial of its gene therapy for Huntington’s disease.

September 2 GuruFocus

QURE Reinstated by William Blair -- Rating Set to Outperform

On September 2, 2026, William Blair reinstated coverage on uniQure (QURE) with a rating of...

September 2 Investor's Business Daily

Embattled Huntington s Gene Therapy Clears A Key Hurdle

Uniqure stock wavered Wednesday after the FDA accepted its application.

September 1 Reuters

uniQure seeks US approval for Huntington s gene therapy after FDA reversal

Dutch gene therapy developer uniQure said on Wednesday it had applied for U.S. approval of its exper...

Never miss news about uniQure

Track uniQure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

uniQure competitors & trending companies

Browse news for competitors to uniQure and other trending companies.